Inhibits the enzyme cyclic adenosine monophosphate (cAMP) phosphodiesterase III (PDE III), which results in increased cAMP in platelets and blood vessels, producing inhibition of platelet aggregation and vasodilation. Therapeutic Effects:
Reduced symptoms of intermittent claudication with improved walking distance. .
•OB: Potential for congenital defects, stillbirth, and low birth weight.
•Lactation: Potential risk to nursing infants; discontinue or bottle feed.
Use Cautiously in:
•Pedi: Safety not established.
Absorption: Slowly absorbed after oral administration.
Protein Binding: 95–98% bound to plasma proteins; one active metabolite is 97.4% bound, the other is 66% bound. Metabolism/Excretion: Extensively metabolized by the liver, two metabolites have platelet aggregation inhibitory activity; metabolites are mostly excreted by the kidneys. Half-life:Cilostazol and its active metabolites — 11–13 hr. Tm/AXN: (effects on platelet function)